InvestSMART

Nova Eye Medical Limited (ASX: EYE) - Announcements

- Current share price for EYE : $0.150

ASX company news and announcements for Nova Eye Medical Limited (EYE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Nova Eye Medical Limited (EYE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Nova Eye Medical Limited (EYE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Nova Eye Medical Limited (EYE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$43 Notification of cessation of securities - EYE 6 Sep 2022 9:31AM $0.260 $0.150 fallen by 42.31%
$43 Appendix 4G and Corporate Governance Statement 26 Aug 2022 10:13AM $0.250 $0.150 fallen by 40%
$43 Investor Presentation FY22 26 Aug 2022 10:12AM $0.250 $0.150 fallen by 40%
$43 Results Announcement FY22 26 Aug 2022 10:11AM $0.250 $0.150 fallen by 40%
$43 Appendix 4E and Annual Report FY22 26 Aug 2022 10:07AM $0.250 $0.150 fallen by 40%
$43 Expiry of Voluntary Escrow Conditions 12 Aug 2022 10:04AM $0.220 $0.150 fallen by 31.82%
$43 Glaucoma Sales update 8 Jul 2022 9:33AM $0.210 $0.150 fallen by 28.57%
$43 iTrack Advance Commercial Roll-Out Commenced 8 Jun 2022 9:01AM $0.210 $0.150 fallen by 28.57%
$43 Notification regarding unquoted securities - EYE 25 May 2022 10:01AM $0.220 $0.150 fallen by 31.82%
$43 Application for quotation of securities - EYE 17 May 2022 4:17PM $0.250 $0.150 fallen by 40%
$43 AlphaRet Investor Presentation 3 May 2022 8:31AM $0.240 $0.150 fallen by 37.50%
$43 2RT Pivotal Study and Regulatory Pathway 3 May 2022 8:30AM $0.240 $0.150 fallen by 37.50%
$43 EYE Representative Appointed to American Glaucoma Society 31 Mar 2022 9:20AM $0.255 $0.150 fallen by 41.18%
$43 Notification regarding unquoted securities - EYE 28 Feb 2022 1:01PM $0.255 $0.150 fallen by 41.18%
$43 Investor presentation Half Year Results 31 December 2021 17 Feb 2022 8:57AM $0.270 $0.150 fallen by 44.44%
$43 Half year results discussion 17 Feb 2022 8:53AM $0.270 $0.150 fallen by 44.44%
$43 Half Yearly Report and Accounts 17 Feb 2022 8:50AM $0.270 $0.150 fallen by 44.44%
$43 Glaucoma Sales Update 1 Feb 2022 9:24AM $0.300 $0.150 fallen by 50%
$43 Reducing Progression Rate Age-Related Macular Degeneration 20 Dec 2021 9:45AM $0.320 $0.150 fallen by 53.13%
$43 Notification regarding unquoted securities - EYE 30 Nov 2021 3:00PM $0.320 $0.150 fallen by 53.13%
$43 Notification regarding unquoted securities - EYE 30 Nov 2021 2:58PM $0.320 $0.150 fallen by 53.13%
$43 Cancel - Proposed issue of securities - EYE 30 Nov 2021 2:37PM $0.320 $0.150 fallen by 53.13%
$43 Notification regarding unquoted securities - EYE 30 Nov 2021 12:06PM $0.320 $0.150 fallen by 53.13%
$43 Appendix 3Z Mr A Sundich 24 Nov 2021 5:48PM $0.370 $0.150 fallen by 59.46%
$43 AGM voting results 24 Nov 2021 4:52PM $0.370 $0.150 fallen by 59.46%

201 - 225 of 352 results

Page 9 of 15

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.